Larimar Therapeutics Inc (LRMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has a cash flow conversion efficiency ratio of -0.493x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.53 Million) by net assets ($78.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Larimar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Larimar Therapeutics Inc for a breakdown of total debt and financial obligations.
Larimar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Larimar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHEMTRONICS.CO.Ltd
KQ:089010
|
-0.110x |
|
Steel Strips Wheels Limited
NSE:SSWL
|
0.058x |
|
Kap Industrial Holdings Ltd
JSE:KAP
|
0.023x |
|
Tianjin Meiteng Technology Co. Ltd. A
SHG:688420
|
N/A |
|
Aic Mines Ltd
AU:A1M
|
0.175x |
|
Gladstone Investment Corporation 8.00% Notes due 2028
NASDAQ:GAINL
|
0.013x |
|
Greenyard NV
BR:GREEN
|
0.189x |
|
IVU Traffic Technologies AG
XETRA:IVU
|
0.126x |
Annual Cash Flow Conversion Efficiency for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Larimar Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.08 Million | $-113.20 Million | -1.450x | -252.00% |
| 2024-12-31 | $171.81 Million | $-70.76 Million | -0.412x | -0.59% |
| 2023-12-31 | $81.72 Million | $-33.46 Million | -0.409x | -64.71% |
| 2022-12-31 | $110.90 Million | $-27.57 Million | -0.249x | +61.97% |
| 2021-12-31 | $64.41 Million | $-42.10 Million | -0.654x | -38.94% |
| 2020-12-31 | $89.69 Million | $-42.20 Million | -0.470x | -101.44% |
| 2019-12-31 | $-694.00K | $-22.70 Million | 32.707x | +6025.11% |
| 2018-12-31 | $93.27 Million | $-51.49 Million | -0.552x | +1.39% |
| 2017-12-31 | $78.22 Million | $-43.78 Million | -0.560x | -31.10% |
| 2016-12-31 | $121.73 Million | $-51.98 Million | -0.427x | -21.25% |
| 2015-12-31 | $169.11 Million | $-59.55 Million | -0.352x | -30.24% |
| 2014-12-31 | $104.44 Million | $-28.24 Million | -0.270x | +36.52% |
| 2013-12-31 | $35.22 Million | $-15.00 Million | -0.426x | +74.75% |
| 2012-12-31 | $8.06 Million | $-13.59 Million | -1.687x | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.